- Home
- ATYR vs ASRT Comparison
ATYR vs ASRT Comparison
Compare ATYR & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATYR
- ASRT
- Stock Information
- Founded
- ATYR 2005
- ASRT 1995
- Country
- ATYR United States
- ASRT United States
- Employees
- ATYR N/A
- ASRT 30
- Industry
- ATYR Biotechnology: Biological Products (No Diagnostic Substances)
- ASRT Biotechnology: Pharmaceutical Preparations
- Sector
- ATYR Health Care
- ASRT Health Care
- Exchange
- ATYR Nasdaq
- ASRT Nasdaq
- Market Cap
- ATYR 126.3M
- ASRT 105.8M
- IPO Year
- ATYR 2015
- ASRT 1997
- Fundamental
- Price
- ATYR $2.23
- ASRT $1.11
- Analyst Decision
- ATYR Strong Buy
- ASRT Strong Buy
- Analyst Count
- ATYR 4
- ASRT 5
- Target Price
- ATYR $19.25
- ASRT $3.35
- AVG Volume (30 Days)
- ATYR 586.5K
- ASRT 449.0K
- Earning Date
- ATYR 11-07-2024
- ASRT 11-06-2024
- Dividend Yield
- ATYR N/A
- ASRT N/A
- EPS Growth
- ATYR N/A
- ASRT N/A
- EPS
- ATYR N/A
- ASRT N/A
- Revenue
- ATYR $588,000.00
- ASRT $132,186,000.00
- Revenue This Year
- ATYR N/A
- ASRT N/A
- Revenue Next Year
- ATYR $2,057.88
- ASRT $4.68
- P/E Ratio
- ATYR N/A
- ASRT N/A
- Revenue Growth
- ATYR N/A
- ASRT N/A
- 52 Week Low
- ATYR $1.08
- ASRT $0.73
- 52 Week High
- ATYR $2.50
- ASRT $2.53
- Technical
- Relative Strength Index (RSI)
- ATYR 74.37
- ASRT 42.06
- Support Level
- ATYR $1.83
- ASRT $1.06
- Resistance Level
- ATYR $1.96
- ASRT $1.14
- Average True Range (ATR)
- ATYR 0.09
- ASRT 0.05
- MACD
- ATYR 0.05
- ASRT -0.01
- Stochastic Oscillator
- ATYR 93.33
- ASRT 26.32
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
About ASRT Assertio Holdings Inc.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older; and Zipsor, liquid-filled capsules for relief of mild to moderate pain.